Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PBAE-447 is a biodegradable cationic poly(β-amino ester) (PBAE) polymer designed for high-efficiency, low-toxicity non-viral gene delivery. Synthesized via Michael addition and end-capping, it is used to encapsulate genetic material, such as plasmid DNA, into nanoparticles. This delivery platform is particularly notable for its ability to overcome transfection barriers in hard-to-transfect cells, such as non-activated primary T cells, which are critical for advanced immunotherapies like CAR-T. By integrating microfluidic co-assembly with PEG or PEG-lipid functionalization (e.g., DMG-PEG2000), PBAE-447 nanoparticles achieve enhanced serum stability and sustained gene expression. The platform aims to simplify CAR-T manufacturing by eliminating the need for in vitro T cell activation and holds potential for direct in vivo gene therapy applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PBAE-447.